Abstract
The management of patients with unruptured aneurysms remains controversial. Patients with unruptured aneurysms may suffer intracranial haemorrhage, but the incidence of this event is still debated; endovascular treatment may prevent rupture, but involves immediate risks. Hence, the balance of risks and benefits of endovascular treatment is uncertain. Here, we report the design of the TEAM trial, the first international, randomized, controlled trial comparing conservative management with endovascular treatment. Primary endpoint is mortality and morbidity (modified Rankin Score ≥ 3) from intracranial haemorrhage or treatment. Secondary endpoints include incidence of hemorrhagic events, morbidity related to endovascular coiling, morphological results, overall clinical outcome and quality of life. Statistical tests compare between probabilities at 5- and 10-years of 1/mortality from haemorrhage related to the lesion, excluding per-operative complications; 2/mortality from haemorrhage or from complications of treatment; 3/combined disease or treatment related mortality and morbidity in the absence of other causes of death or disability. The study will be conducted in 60 international centres and will enrol 2,002 patients equally divided between the two groups, a size sufficient to achieve 80% power at a 0.0167 significance to detect differences in 1) disease or treatment-related poor outcomes from 7–9% to 3–5%; 2) overall mortality from 16 to 11%. Duration of the study is 14 years, the first three years being for patient recruitment plus a minimum of 10 years of follow-up. The TEAM trial thus offers a means to reconcile the introduction of a new approach with the necessity to acknowledge uncertainties.
Trial registration
Current Controlled Trials ISRCTN62758344 http://www.controlled-trials.com
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 CHUM Notre-Dame Hospital, TEAM coordinating centre, Interventional Neuroradiology Research Unit, Department of Radiology, Montreal, Canada (GRID:grid.414246.1) (ISNI:0000000403776832)
2 John Radcliffe Hospital, Oxford Neurovascular & Neuroradiology Research Unit, Level 6, West Wing, Oxford, UK (GRID:grid.8348.7) (ISNI:0000000123067492)
3 Sunnybrook Health Sciences Centre, Department of Medical Imaging, Ontario, Canada (GRID:grid.413104.3) (ISNI:0000000097431587)
4 University of California at San Francisco, UCSF Neurovascular Disease and Stroke Centre, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000000122976811)
5 University of British Columbia, Centre for Healthcare Innovation and Improvement, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000000122889830)
6 Centre de Neurosciences de la Cognition, Département de Psychologie, Montreal, Canada (GRID:grid.17091.3e)